QuantumCyte’s AI-guided digital pathology approach targets a practical bottleneck in solid-tumor genomics: low tumor-cell purity in biopsies. The method identifies tumor borders on slides and masks healthy tissue to enrich tumor DNA for sequencing, aiming to improve the proportion of patients who can receive actionable molecular results. The central operational gain is reducing the “tumor DNA content” failure mode that can prevent reference labs from producing clinically reportable genomic outputs. The company frames the problem as physical contamination rather than purely analytical limitations, positioning pathology image analysis plus automated masking as a key intervention point. If adopted broadly, the workflow could shift liquid biopsy and tissue selection strategies by improving the reliability of tumor profiling from limited samples—especially in settings where repeat biopsy is not feasible.